Chelsea L Shover1, Keith Humphreys2. 1. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Rd. (MC: 5717), Stanford, CA 94305, United States. Electronic address: clshover@stanford.edu. 2. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Rd. (MC: 5717), Stanford, CA 94305, United States; Veterans Affairs Palo Alto Health Care System, 3801 Miranda Ave (152-MPD), Palo Alto, CA 94304, United States. Electronic address: knh@stanford.edu.
Abstract
BACKGROUND: The U.S. Food and Drug Administration has approved three long-acting medications for opioid use disorder (MOUD): extended-release naltrexone (XR-NTX) in 2010, a subdermal buprenorphine implant in 2016, and a depot buprenorphine injection in 2017. Long-acting MOUD options may improve adherence while reducing diversion, but their availability compared to daily-dosing MOUD has not been well-characterized. The objective of this analysis was to characterize the availability of long-acting MOUD in substance use disorder treatment settings in the United States. METHODS: Using the 2017 National Survey on Substance Abuse Treatment Services (N-SSATS) and state-level opioid overdose mortality, we examined associations between state- and facility-level factors and offering long-acting MOUD, which included XR-NTX and the buprenorphine implant. We constructed multivariable mixed logistic regression models for both types of long-acting MOUD. RESULTS: Nationwide, 38% (n = 5141) of substance use treatment facilities provided any kind of MOUD (daily or long-acting). Of these, 62% provided XR-NTX, whereas only 3% offered the buprenorphine implant. Facilities in the East North Central, East South Central, West North Central and Mountain regions had higher odds of offering XR-NTX, as did federally-funded facilities, and facilities in states with the highest opioid overdose mortality rates. CONCLUSIONS: In 2017, XR-NTX was available at most of the minority of facilities offering MOUD, but the buprenorphine implant was not. Increasing the availability of MOUD, including long-acting options, is necessary to address unmet need for opioid use disorder treatment.
BACKGROUND: The U.S. Food and Drug Administration has approved three long-acting medications for opioid use disorder (MOUD): extended-release naltrexone (XR-NTX) in 2010, a subdermal buprenorphine implant in 2016, and a depot buprenorphine injection in 2017. Long-acting MOUD options may improve adherence while reducing diversion, but their availability compared to daily-dosing MOUD has not been well-characterized. The objective of this analysis was to characterize the availability of long-acting MOUD in substance use disorder treatment settings in the United States. METHODS: Using the 2017 National Survey on Substance Abuse Treatment Services (N-SSATS) and state-level opioid overdosemortality, we examined associations between state- and facility-level factors and offering long-acting MOUD, which included XR-NTX and the buprenorphine implant. We constructed multivariable mixed logistic regression models for both types of long-acting MOUD. RESULTS: Nationwide, 38% (n = 5141) of substance use treatment facilities provided any kind of MOUD (daily or long-acting). Of these, 62% provided XR-NTX, whereas only 3% offered the buprenorphine implant. Facilities in the East North Central, East South Central, West North Central and Mountain regions had higher odds of offering XR-NTX, as did federally-funded facilities, and facilities in states with the highest opioid overdosemortality rates. CONCLUSIONS: In 2017, XR-NTX was available at most of the minority of facilities offering MOUD, but the buprenorphine implant was not. Increasing the availability of MOUD, including long-acting options, is necessary to address unmet need for opioid use disorder treatment.
Authors: Richard N Rosenthal; Michelle R Lofwall; Sonnie Kim; Michael Chen; Katherine L Beebe; Frank J Vocci Journal: JAMA Date: 2016-07-19 Impact factor: 56.272
Authors: Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz Journal: Am J Public Health Date: 2015-06-11 Impact factor: 9.308
Authors: Barbara L Shacklett; Julià Blanco; Lisa Hightow-Weidman; Nyaradzo Mgodi; José Alcamí; Susan Buchbinder; Mike Chirenje; Smritee Dabee; Mamadou Diallo; Kostyantyn Dumchev; Carolina Herrera; Matthew E Levy; Enrique Martin Gayo; Nigel Aminake Makoah; Kate M Mitchell; Kenneth Mugwanya; Krishnaveni Reddy; Maria Luisa Rodríguez; Marta Rodriguez-Garcia; Chelsea L Shover; Tripti Shrivastava; Georgia Tomaras; Michiel Van Diepen; Monika Walia; Mitchell Warren; Amapola Manrique; Bargavi Thyagarajan; Tamara Torri Journal: AIDS Res Hum Retroviruses Date: 2019-05-29 Impact factor: 2.205
Authors: Keith Humphreys; Chelsea L Shover; Christina M Andrews; Amy S B Bohnert; Margaret L Brandeau; Jonathan P Caulkins; Jonathan H Chen; Mariano-Florentino Cuéllar; Yasmin L Hurd; David N Juurlink; Howard K Koh; Erin E Krebs; Anna Lembke; Sean C Mackey; Lisa Larrimore Ouellette; Brian Suffoletto; Christine Timko Journal: Lancet Date: 2022-02-02 Impact factor: 202.731
Authors: Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch Journal: Addict Sci Clin Pract Date: 2021-01-27
Authors: Jake R Morgan; Joshua A Barocas; Sean M Murphy; Rachel L Epstein; Michael D Stein; Bruce R Schackman; Alexander Y Walley; Benjamin P Linas Journal: JAMA Netw Open Date: 2020-12-01